Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 2
2020 pubmed 8 citations

On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.

Reverter-Branchat. Gemma G; Segura. Jordi J; Pozo. Oscar J OJ

Key Findings

  • Limit of detection for GHRP‑2 is 50 pg/ml using DBS LC‑MS/MS
  • GHRP‑2 can be detected up to 4 hours after a 100 µg intravenous dose
  • DBS samples remain stable for more than 2 years
  • Venous blood DBS shows higher GHRP‑2 levels than capillary DBS, but detection windows are similar
  • The main metabolite AA‑3 is too low in DBS to be reliably measured

Practical Outcomes

  • For DIY users, a finger‑prick dried blood spot could be used to confirm recent GHRP‑2 use within a short window (a few hours). However, the test isn’t sensitive enough for low‑dose or long‑term detection, and measuring the metabolite isn’t reliable. The method’s long‑term stability means samples can be stored and shipped easily.

Summary

Scientists created a simple finger‑prick blood test (dried blood spots) that can spot the peptide GHRP‑2 in the body. It can detect very tiny amounts (50 pg/ml) and works for at least a few hours after a single 100 µg IV dose, staying stable for years when stored.

Abstract

Dried blood spots (DBSs) sampling is gaining support by the antidoping community because of simplicity and cost-effective characteristics, especially in collection, transport, and storage. Nevertheless, DBS applicability demands specific studies for each of the analytes proposed for testing. Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing. An analytical procedure to extract GHRP-2 and its main metabolite (AA-3) from DBS and to detect them by liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed. The method has been validated for the detection of GHRP-2. Specificity and identification capabilities have been assessed in agreement with antidoping guidelines. The low AA-3 levels found in DBS samples prevented its effective application for the determination of this metabolite. The limit of detection (LoD) for GHRP-2 has been established at 50 pg/ml. Long-term stability (>2 years) has been confirmed. The procedure has been successfully applied to actual DBS samples from an administration study with a single intravenous dose of GHRP-2 (100 μg) being detected up to 4 h after drug injection. GHRP-2 concentrations have been higher in venous blood DBS than in capillary blood DBS. Despite the observed differences, a similar detection window has been achieved independently of the type of blood used. In summary, this study provides specific evidence supporting DBS usefulness to detect GHRP-2, and potentially other GHRPs family members, for antidoping tests.

Study Information

Provider

pubmed

Year

2020

Date

2020-11-25T00:00:00.000Z

DOI

10.1002/dta.2975

Citations

8

References

34